Webinar Date/Time: Thurs, September 19, 2024 Session 1: 9:00am EDT | 1:00pm GMT | 2:00pm CET Session 2: 1:00pm EDT| 5:00pm GMT | 6:00 am CET
The highest DBC form Ab capture step with mild elution pH, low aggregate, low HCP and DNA are demonstrated using a newly developed Super protein A resin.
Register Free: https://www.biopharminternational.com/bp_w/chromatography-resin
Event Overview:
Technical data from a newly developed Super protein A resin shows that it can improve mAb purification process economy and robustness for the capture step. Experimental data demonstrates its alkaline stability is exceptionally good and allows effective CIP using a very high alkaline condition while still maintaining its highest dynamic binding capacity after many cycles. Data also shows that elution with high or milder pH condition can be achieved to reduce aggregation of the monomer eluate. Moreover, low HCP, low DNA, and low protein A leakage make polishing steps more effective.
Key Learning Objectives:
Who Should Attend:
Speaker:
Phu Duong, PhD
Senior Manager of Product Management – Americas
Tosoh Bioscience, LLC
Phu Duong, PhD, earned his degree in 2003 from Temple University, Philadelphia, Pennsylvania. He has held various roles in the marketing and technical service departments at Tosoh Bioscience. Currently, Dr Duong is leading product management (Americas) for all product lines. His expertise is in developing the strategy for the growth of the consumable and capital equipment portfolios and commercializing new products to support the biotherapeutics market.
Register Free: https://www.biopharminternational.com/bp_w/chromatography-resin
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.